Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) kicked off on Friday, up 5.31% from the previous trading day, before settling in for the closing price of $438.40. Over the past 52 weeks, VRTX has traded in a range of $377.85-$519.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 25.08%. While this was happening, its average annual earnings per share was recorded -96.82%. With a float of $256.84 million, this company’s outstanding shares have now reached $257.74 million.
Let’s determine the extent of company efficiency that accounts for 5400 employees. In terms of profitability, gross margin is 86.1%, operating margin of -2.96%, and the pretax margin is 2.45%.
Vertex Pharmaceuticals, Inc (VRTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Vertex Pharmaceuticals, Inc is 0.25%, while institutional ownership is 92.52%. The most recent insider transaction that took place on Nov 15 ’24, was worth 7,178. In this transaction EVP, Chief Scientific Officer of this company sold 15 shares at a rate of $478.56, taking the stock ownership to the 25,813 shares. Before that another transaction happened on Nov 15 ’24, when Company’s Officer proposed sale 15 for $478.56, making the entire transaction worth $7,178.
Vertex Pharmaceuticals, Inc (VRTX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -96.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.68% during the next five years compared to 11.42% growth over the previous five years of trading.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Trading Performance Indicators
Take a look at Vertex Pharmaceuticals, Inc’s (VRTX) current performance indicators. Last quarter, stock had a quick ratio of 2.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.99, a number that is poised to hit 4.01 in the next quarter and is forecasted to reach 18.56 in one year’s time.
Technical Analysis of Vertex Pharmaceuticals, Inc (VRTX)
Looking closely at Vertex Pharmaceuticals, Inc (NASDAQ: VRTX), its last 5-days average volume was 1.72 million, which is a jump from its year-to-date volume of 1.59 million. As of the previous 9 days, the stock’s Stochastic %D was 75.62%. Additionally, its Average True Range was 12.56.
During the past 100 days, Vertex Pharmaceuticals, Inc’s (VRTX) raw stochastic average was set at 59.02%, which indicates a significant decrease from 86.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.06% in the past 14 days, which was lower than the 32.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $437.71, while its 200-day Moving Average is $459.00. However, in the short run, Vertex Pharmaceuticals, Inc’s stock first resistance to watch stands at $473.41. Second resistance stands at $485.15. The third major resistance level sits at $498.25. If the price goes on to break the first support level at $448.57, it is likely to go to the next support level at $435.47. Now, if the price goes above the second support level, the third support stands at $423.73.
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) Key Stats
The company with the Market Capitalisation of 118.90 billion has total of 257,529K Shares Outstanding. Its annual sales at the moment are 9,869 M in contrast with the sum of 3,620 M annual income. Company’s last quarter sales were recorded 2,772 M and last quarter income was 1,045 M.
